Internal Medicine, Infectious Disease · Portland, OR
NPI
1679509525
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3375 SW Terwilliger Blvd
Portland, OR, 97239
Phone (503) 494-7890
Groups this clinician bills Medicare through
Medicare paid, 2024
$22K
401 services
Medicare patients, 2024
104
Average age 76
Drug cost, 2024
$493K
832 prescriptions
Company payments, 2025
$551K
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kevin L Winthrop was code 99214 (office e&m - established), 119 times for 59 patients. In total Kevin L Winthrop billed 401 services in 7 codes, and Medicare paid $22K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-01-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 119 | 59 | $70.21 | $8,355 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 101 | 58 | $13.53 | $1,367 |
| 99214 Office E&M - Established | Office | 58 | 37 | $70.21 | $4,072 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 55 | 44 | $13.32 | $732 |
| 99215 Office E&M - Established | Facility | 21 | 16 | $114.04 | $2,395 |
By year: 2022 $18K for 222 services; 2023 $18K for 230 services; 2024 $22K for 401 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kevin L Winthrop prescribed most often to Medicare patients was Azithromycin, with 215 prescriptions and refills. In total Kevin L Winthrop wrote 832 Medicare prescriptions that cost $493K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Azithromycin Generic | 215 | 329 | 49 | $7,779 |
| Ethambutol Hcl Generic | 196 | 287 | 45 | $14K |
| Rifampin Generic | 100 | 162 | 22 | $6,669 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 30 | 35 | 21 | $860 |
| Doxycycline Monohydrate Generic | 30 | 30 | 22 | $254 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 28 | 28 | Under 11 | $16K |
| Amikacin Sulfate Generic | 27 | 27 | Under 11 | $1,752 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 25 | 30 | Under 11 | $2,978 |
| Nuzyra Omadacycline Tosylate | 21 | 21 | Under 11 | $106K |
| Arikayce Amikacin Liposomal/Neb.Accessr | 20 | 29 | Under 11 | $310K |
| Levofloxacin Generic | 15 | 15 | 11 | $136 |
| Colistimethate Colistin (Colistimethate Na) | 13 | 28 | Under 11 | $13K |
| Gabapentin Generic | 13 | 13 | Under 11 | $32.39 |
Brand drugs: - claims; generic drugs: 707 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kevin L Winthrop $551K ($289K in general payments such as food, travel and fees and $261K for research) from 30 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $126K.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $126K |
| Genentech, Inc. ROG.SW | 22 | $86K |
| Eli Lilly and Company LLY | 4 | $61K |
| Bausch Health US, LLC BHC | 10 | $50K |
| Abbvie Inc. ABBV | 11 | $47K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 9 | $31K |
| GlaxoSmithKline, LLC. GSK | 2 | $22K |
| ModernaTX, Inc. MRNA | 7 | $20K |
| Otsuka Pharmaceutical Development & Commercialization, Inc. 4578.T | 5 | $16K |
| Insmed, Inc. INSM | 6 | $16K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.